We need to listen to the voices of those historically underrepresented in research and demonstrate how clinical trials may be a viable care option for them. I firmly believe these efforts will directly improve the pervasive access and diversity issues that continue to impact participation rates in research.
When some experience sparks a “rocket launch” of an idea in an entrepreneur’s soul for a disruptive new service or product in the clinical research environment, listening to one’s inner voice is important, but listening to the patients who may benefit if the idea succeeds is most important, a panel of experts told ACRP 2023 attendees Monday morning (May 1) in Dallas, Texas.
While questions about what decentralized clinical trials (DCTs) are may have been largely resolved in the minds of most clinical research professionals by now, the reactions to several polling questions on Sunday (April 30) from attendees at the ACRP 2023 conference in Dallas, Texas, suggest strongly that opinions in the field on some aspects of how, when, and why they should be implemented remain divided.